Meribank Biotech Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	471.76	366.43	234.34	180.12	163.08
Revenue Growth (YoY)	28.75%	56.36%	30.10%	10.45%	-16.11%
Cost of Revenue	269.59	172.49	95.47	85.35	73.02
Gross Profit	202.18	193.94	138.87	94.77	90.06
Selling, General & Admin	218.24	244.72	221.9	179.2	165.88
Research & Development	31.26	35.9	35.48	25.94	16.11
Operating Expenses	254.96	281.84	261.23	204.55	187.27
Operating Income	-52.78	-87.9	-122.36	-109.78	-97.22
Interest Expense	-23.11	-10.7	-0.85	-0.99	-1.13
Interest & Investment Income	2.55	2.53	1.86	1.27	0.48
Earnings From Equity Investments	-3.63	-11.93	-5.41	-5.42	-4.51
Other Non Operating Income (Expenses)	-11.97	11.18	2.48	11.69	2.98
EBT Excluding Unusual Items	-88.94	-96.81	-124.28	-103.23	-99.39
Impairment of Goodwill	-	-	-5.67	-	-
Gain (Loss) on Sale of Investments	-	-4.73	-	-	0.18
Other Unusual Items	-	-	-	-	0.02
Pretax Income	-88.94	-101.55	-129.95	-103.23	-99.19
Income Tax Expense	-6.78	-4.61	-0.44	-0.08	-
Earnings From Continuing Operations	-82.16	-96.94	-129.51	-103.15	-99.19
Minority Interest in Earnings	0.7	2.23	4.16	1.01	-
Net Income	-81.47	-94.71	-125.35	-102.13	-99.19
Net Income to Common	-81.47	-94.71	-125.35	-102.13	-99.19
Shares Outstanding (Basic)	92	80	63	63	60
Shares Outstanding (Diluted)	92	80	63	63	60
Shares Change (YoY)	15.10%	26.54%	0.11%	4.07%	14.52%
EPS (Basic)	-0.89	-1.19	-1.99	-1.63	-1.64
EPS (Diluted)	-0.89	-1.19	-1.99	-1.63	-1.64
Free Cash Flow	85.62	-286.7	-35.5	-45.48	-30.2
Free Cash Flow Per Share	0.94	-3.60	-0.56	-0.72	-0.50
Gross Margin	42.86%	52.93%	59.26%	52.62%	55.22%
Operating Margin	-11.19%	-23.99%	-52.21%	-60.95%	-59.61%
Profit Margin	-17.27%	-25.85%	-53.49%	-56.70%	-60.83%
Free Cash Flow Margin	18.15%	-78.24%	-15.15%	-25.25%	-18.52%
EBITDA	102.63	-50.76	-110.86	-98.08	-86.11
EBITDA Margin	21.75%	-13.85%	-47.31%	-54.45%	-52.80%
D&A For EBITDA	155.41	37.14	11.49	11.7	11.11
EBIT	-52.78	-87.9	-122.36	-109.78	-97.22
EBIT Margin	-11.19%	-23.99%	-52.21%	-60.95%	-59.61%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.